Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959667 | 0.82 | ALDH1A1 (0.36) | ALDH1A1GLALMNAPDE7A | |
| SCHEMBL27283771 | 0.76 | ALDH1A1 (0.47) | ALDH1A1GLALMNAPDE7APOLB | |
| SCHEMBL28651135 | 0.76 | ALDH1A1 (0.61) | ALDH1A1GLALMNAKDM4EMEN1 | |
| SCHEMBL25314143 | 0.75 | ALDH1A1 (0.51) | ALDH1A1GLALMNAKDM4EPOLB | |
| SCHEMBL3293088 | 0.73 | ALDH1A1 (0.63) | ALDH1A1GLALMNAKDM4EMEN1 | |
| SCHEMBL11645181 | 0.72 | ALDH1A1 (0.61) | ALDH1A1GLALMNAKDM4EPOLB | |
| SCHEMBL10651010 | 0.72 | ALDH1A1 (0.61) | ALDH1A1GLAPDE7AKDM4EMEN1 | |
| SCHEMBL2070952 | 0.72 | ALDH1A1 (0.61) | ALDH1A1GLAKDM4ECYP3A4TSHR | |
| SCHEMBL28282461 | 0.72 | ALDH1A1 (1.00) | ALDH1A1GLALMNAKDM4EMEN1 | |
| SCHEMBL1849598 | 0.71 | GLA (0.56) | ALDH1A1GLALMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | SCRIPPS RESEARCH INST (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| EP-4472942-A2 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | The Scripps Research Institute (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-09-05 | — | — | US | disclosed |
| WO-2023147545-A9 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-118355004-A | Cyclopropyl- (heteroaryl) -substituted ethylsulfonyl-pyridine derivatives | 勃林格殷格翰动物保健有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4385574-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of the University of California (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-03 | — | — | US | disclosed |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-06 | — | — | US | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| EP-2004181-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | The Regents of the University of California (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007126765-A2 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293383-A1 | SUBSTITUTED DIAZASPIROALKANES AS ANDROGEN RECEPTOR MODULATORS | AR, HRAS, NR5A1 | ALDH1A1 498/4885GLA 2882/4885LMNA 3194/4885 |
| US-11771687-B2 | Substituted diazaspiroalkanes as androgen receptor modulators | AR, HRAS, NR5A1 | ALDH1A1 498/4885GLA 2882/4885LMNA 3194/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | ALDH1A1 1025/4885GLA 1177/4885LMNA 4318/4885 |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | ALDH1A1 1223/4885GLA 3769/4885LMNA 2946/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | ALDH1A1 1426/4885GLA 2220/4885LMNA 1761/4885 |
| US-20110003839-A1 | ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES | AR, NR5A1, SHBG | ALDH1A1 991/4885GLA 1410/4885LMNA 2971/4885 |
| US-12435083-B2 | Cyclopropyl-(hetero)aryl-substituted ethylsulphonyl-pyridine derivatives | CYCS, CYP2E1, CYP1A1 | ALDH1A1 512/4885GLA 3720/4885LMNA 4491/4885 |
| US-20260001830-A1 | PROCESS FOR PD(II)-CATALYZED SITE-SELECTIVE BETA- AND GAMMA-C(SP3)-H ARYLATION OF PRIMARY ALDEHYDES CONTROLLED BY TRANSIENT DIRECTING GROUPS | PDCD1LG2, PDCD1, CD274 | ALDH1A1 177/4885GLA 1569/4885LMNA 2269/4885 |
| US-20260103464-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CBR3, CYCS, CBR1 | ALDH1A1 2267/4885GLA 3962/4885LMNA 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.